Article
Physiology
Aihua Lu, Min Pu, Shiqi Mo, Jiahui Su, Jiajia Hu, Chunling Li, Weidong Wang, Tianxin Yang
Summary: This study identified a novel role of (pro)renin receptor (PRR) in mediating the phosphaturic response to phosphate treatment. Activation of PRR promotes the production of FGF23, which in turn downregulates the expression of renal Na/Pi-IIa and enhances phosphate excretion.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Urology & Nephrology
Naohiko Fujii, Takayuki Hamano, Jesse Y. Hsu, Enyu Imai, Tadao Akizawa, Kosaku Nitta, Tsuyoshi Watanabe, Satoshi Iimuro, Yasuo Ohashi, Seiichi Matsuo, Hirofumi Makino, Akira Hishida, Arnold B. Alper, Edward J. Horwitz, Chi-Yuan Hsu, Anna C. Porter, Myles Wolf, Wei Yang, Lisa Nessel, Harold I. Feldman
Summary: Recent studies have shown a higher incidence of cardiovascular disease among CKD patients in the USA compared to Japan. Hyperphosphatemia may explain this difference.
AMERICAN JOURNAL OF NEPHROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Beatrice Richter, Tamar Kapanadze, Nina Weingaertner, Stefanie Walter, Isabel Vogt, Andrea Grund, Jessica Schmitz, Jan Hinrich Braesen, Florian P. Limbourg, Dieter Haffner, Maren Leifheit-Nestler
Summary: High phosphate intake may lead to progressive kidney injury and represents an underestimated health problem for kidney health.
Article
Endocrinology & Metabolism
K. Berit Sellars, Brittany A. Ryan, Sarah A. Hartery, Beth J. Kirby, Christopher S. Kovacs
Summary: FGF23 appears to play no role in fetal phosphorus metabolism before birth, but maternal phosphate loading can induce a fetal FGF23 response without affecting fetal serum phosphorus levels.
Review
Endocrinology & Metabolism
Monika Martiniakova, Vladimira Mondockova, Roman Biro, Veronika Kovacova, Martina Babikova, Nina Zemanova, Sona Ciernikova, Radoslav Omelka
Summary: The skeleton is a common site of metastatic disease, particularly in prostate and breast cancers, leading to bone complications and poor prognosis. The interaction between bone cells and tumor cells is crucial in the development of bone metastasis. Several bone-derived factors, including OC, ucOC, FGF23, SCL, and LCN2, have been identified as potential tumor biomarkers and therapeutic targets. Targeting these factors may offer new approaches in the prevention and treatment of bone metastasis.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, General & Internal
Altynay Balmukhanova, Kairat Kabulbayev, Harika Alpay, Assiya Kanatbayeva, Aigul Balmukhanova
Summary: The study found that FGF-23 levels increased early in children with CKD, showing significant differences as the disease progressed. FGF-23 was correlated with PTH and phosphate levels, suggesting it could be a key biomarker in kidney disease progression.
MEDICINA-LITHUANIA
(2021)
Article
Endocrinology & Metabolism
Fahad Aljuraibah, Justine Bacchetta, Maria Luisa Brandi, Pablo Florenzano, Muhammad K. Javaid, Outimaija Makitie, Adalbert Raimann, Mariano Rodriguez, Heide Siggelkow, Dov Tiosano, Marc Vervloet, Carsten A. Wagner
Summary: Chronic hypophosphatemia, characterized by low phosphate levels, can lead to underrecognition and poor clinical outcomes. Understanding phosphate homeostasis and early diagnosis are crucial for optimal management and improved health outcomes.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Article
Sport Sciences
Katharina Kerschan-Schindl, Katerina Skenderi, Katharina Wahl-Figlash, Katharina Gelles, Urusla Foeger-Samwald, Markus Thalmann, Maria Tsironi, Thoms Szekeres, Peter Pietschmann
Summary: This observational study found that participation in an ultradistance run led to an overexpression of the phosphaturic hormone FGF23, which may contribute to the short-term uncoupling of bone metabolism.
JOURNAL OF SCIENCE AND MEDICINE IN SPORT
(2021)
Review
Cell Biology
Krittikan Chanpaisaeng, Jarinthorn Teerapornpuntakit, Kannikar Wongdee, Narattaphol Charoenphandhu
Summary: For decades, the ability of intestinal mucosal cells to sense calcium levels has been a mystery. Recent studies have shown that enterocytes can use CaSR to monitor and regulate extracellular calcium levels, thereby limiting calcium absorption through a negative feedback loop.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2021)
Article
Urology & Nephrology
Kittrawee Kritmetapak, Louis Losbanos, Taylor E. Berent, Susan L. Ashrafzadeh-Kian, Alicia Algeciras-Schimnich, Jolaine M. Hines, Ravinder J. Singh, Rajiv Kumar
Summary: In early stages of chronic kidney disease, compensatory decreases in circulating 1,25-hydroxyvitamin D and increases in circulating intact FGF23 and PTH facilitate the normalization of serum phosphate concentration, while no significant changes were observed in circulating intact FGF7. Further studies are needed to investigate whether other circulating phosphaturic peptides change in response to phosphate retention in CKD patients.
Article
Multidisciplinary Sciences
Jingzhu Zhang, Adi Cohen, Bo Shen, Liming Du, Alpaslan Tasdogan, Zhiyu Zhao, Elizabeth J. Shane, Sean J. Morrison
Summary: The study revealed that PTH promotes osteolectin expression and its interaction mediates part of the bone formation response to PTH, while SOSTi does not affect osteolectin levels or require it for bone formation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Endocrinology & Metabolism
Ignacio Portales-Castillo, Petra Simic
Summary: Bone-mineral ion regulators, such as PTH, FGF23, Klotho, and 1,25(OH)2 vitamin D, play important roles in calcium and phosphate metabolism and cell signaling. These factors are tightly regulated through genetic, epigenetic, and post-translational mechanisms. Epigenetic mechanisms, including DNA methylation and histone modification, have been found to affect the function of these regulators.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Physiology
Catharina J. Ku, Betul Haykri, Udo Schnitzbauer, Daniela Egli-Spichtig, Nati Hernando, Carsten A. Wagner
Summary: FGF23 regulates NaPi-IIa and NaPi-IIc through ERK1/2 signaling pathway, reducing plasma calcitriol levels and causing internalization of these cotransporters within 2 hours.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
(2021)
Article
Endocrinology & Metabolism
Yuichi Takashi, Kyoko Toyokawa, Naoki Oda, Yoshimi Muta, Hisashi Yokomizo, Seiji Fukumoto, Daiji Kawanami
Summary: This report describes a case of adult XLH and tertiary hyperparathyroidism, finding that serum phosphate levels remained low despite burosumab treatment. Treatment with the calcimimetic evocalcet increased serum phosphate levels and tubular maximum reabsorption of phosphate. Therefore, evaluating the presence of hyperparathyroidism is important in patients whose serum phosphate levels do not increase with burosumab treatment.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Won-Taek Oh, Yeon-Suk Yang, Jun Xie, Hong Ma, Jung-Min Kim, Kwang-Hwan Park, Daniel S. Oh, Kyung-Hyun Park-Min, Matthew B. Greenblatt, Guangping Gao, Jae-Hyuck Shim
Summary: Recombinant adeno-associated virus (rAAV)-mediated gene therapy shows promise as a long-lasting and targeted treatment for osteoporosis and associated bone fractures. By silencing the expression of WNT antagonists, SHN3 and SOST, and enhancing WNT/β-catenin signaling, osteoblast function, and bone formation, this approach effectively reverses bone loss and improves fracture healing. These findings demonstrate the clinical potential of bone-specific gene silencers for treating skeletal disorders.